Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Samalizumab · ALXN-6000

Monoclonal antibody · Antagonist of CD200 · developed by Alexion Pharmaceuticals

Phase 2/3 Most advanced trial
1 Registered trials

What is Samalizumab?

Samalizumab is a humanized monoclonal antibody that binds CD200, blocking its interaction with CD200R on macrophages and other immune cells. By inhibiting CD200-mediated immunosuppression, it augments cytotoxic T-lymphocyte responses against CD200-expressing tumor cells. It is studied in relapsed/refractory acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ALXN-6000
Drug type
Monoclonal antibody
Targets
CD200, CD200R (CD200R1) (binding partner it blocks)
Mechanism
Antagonist of CD200
Pathways
T cell activation, immune response augmentation
Therapy area
Hematology, Oncology
Developer
Alexion Pharmaceuticals, Inc.
In trials of
SNDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
64EUX713G6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03013998 Phase 2/3 Previously Untreated Relapsed Refractory Acute Myeloid Leukemia Recruiting SNDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.